Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.51 |
| ▸ | F12 | P00748 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119861 | 0.81 | PTGS2 (0.52) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL17666232 | 0.74 | F12 (0.60) | ESR1ESR2F12TDP1GRIN1 | |
| SCHEMBL19411892 | 0.74 | F12 (0.60) | ESR1ESR2F12TDP1GRIN1 | |
| SCHEMBL8328537 | 0.71 | MEN1 (0.73) | ESR1ESR2HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL8328551 | 0.69 | MEN1 (0.70) | ESR1ESR2HTR3EHTR3BHTR3A | |
| SCHEMBL30199292 | 0.69 | CYP1A2 (0.56) | ESR1ESR2F12CYP2D6CYP2C19 | |
| SCHEMBL6356758 | 0.69 | CYP1A2 (0.56) | ESR1ESR2F12CYP2D6CYP2C19 | |
| SCHEMBL23411272 | 0.68 | PLG (0.53) | ESR1ESR2HTR3EHTR3BHTR3A | |
| SCHEMBL4856119 | 0.68 | NOS3 (0.58) | ESR1ESR2HTR3EHTR3BHTR3A | |
| SCHEMBL4864124 | 0.68 | NOS3 (0.58) | ESR1ESR2HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423149-B2 | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| CN-1918114-A | Substituted n-aryl amidines as selective d1 dopamine receptor antagonists for the treatment of obesity and cns disorders | SCHERING CORP (US) | 2007-02-21 | — | — | CN | disclosed |
| EP-1706375-A2 | SUBSTITUTED N-ARYL AMIDINES AS SELECTIVE D1 DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND CNS DISORDERS | SCHERING CORPORATION (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005063697-A2 | SUBSTITUTED N-ARYL AMIDINES AS SELECTIVE D1 DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND CNS DISORDERS | SCHERING CORPORATION (US) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137210-A1 | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137210-A1 | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders | GPR119, GLP1R, DRD1 | ESR1 478/4885ESR2 1564/4885F12 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.